Anika Therapeutics (ANIK) financial statements
Anika Therapeutics reported revenue of $113M in fiscal 2025, up 1.0% a year over 9 years.
Net income was -$11M and the operating margin -9.8%, against 49.0% in 2016.
Free cash flow was $4M, and the company returned $9M in net buybacks.
The diluted share count fell 5% over the period (buybacks).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Anika Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $103M | $113M | $106M | $115M | $130M | $148M | $114M | $121M | $120M | $113M |
| Cost of revenue | $24M | $27M | $31M | $29M | $61M | $65M | $41M | $38M | $44M | $49M |
| Gross profit | $79M | $86M | $74M | $86M | $69M | $83M | $73M | $83M | $76M | $64M |
| Research and development | $11M | $19M | $18M | $17M | $23M | $27M | $18M | $22M | $26M | $26M |
| Selling, general and admin | $18M | $22M | $34M | $35M | $60M | $74M | $51M | $60M | $56M | $49M |
| Operating income | $51M | $46M | $22M | $34M | -$28M | $3M | $4M | $844,000 | -$5M | -$11M |
| Pre-tax income | $51M | $46M | $23M | $36M | -$29M | $2M | $4M | $3M | -$3M | -$9M |
| Income tax | $18M | $14M | $4M | $9M | -$5M | -$2M | $2M | $7M | $6M | $672,000 |
| Net income | $33M | $32M | $19M | $27M | -$24M | $4M | -$15M | -$83M | -$56M | -$11M |
| EPS (diluted) | $2.15 | $2.11 | $1.27 | $1.89 | -$1.69 | $0.28 | -$1.02 | -$5.64 | -$3.83 | -$0.76 |
| Diluted shares | 15M | 15M | 15M | 14M | 14M | 15M | 15M | 15M | 15M | 14M |
| Gross margin | 76.8% | 75.9% | 70.4% | 74.9% | 52.9% | 56.1% | 64.3% | 68.3% | 63.4% | 56.6% |
| Operating margin | 49.0% | 40.3% | 20.6% | 29.9% | -21.7% | 1.8% | 3.2% | 0.7% | -4.3% | -9.8% |
| Net margin | 31.5% | 28.1% | 17.7% | 23.7% | -18.4% | 2.8% | -13.1% | -68.4% | -47.0% | -9.6% |
Balance sheet
Fiscal years, from Anika Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $125M | $157M | $159M | $185M | $98M | $124M | $121M | $95M | $79M | $81M |
| Receivables | $28M | $24M | $21M | $23M | $24M | $30M | $35M | $26M | $24M | $24M |
| Inventory | $16M | $22M | $21M | $22M | $46M | $36M | $40M | $24M | $24M | $19M |
| Total current assets | $170M | $206M | $203M | $234M | $177M | $169M | $170M | $163M | $114M | $103M |
| Property, plant and equipment | $52M | $56M | $54M | $51M | $51M | $48M | $48M | $37M | $39M | $40M |
| Goodwill | $7M | $8M | $8M | $8M | $8M | $8M | $7M | $8M | $7M | $8M |
| Total assets | $240M | $283M | $279M | $331M | $366M | $348M | $349M | $271M | $203M | $190M |
| Total current liabilities | $9M | $13M | $11M | $16M | $37M | $30M | $28M | $31M | $23M | $22M |
| Long-term debt | — | — | — | $0 | — | — | — | — | — | — |
| Total liabilities | $17M | $19M | $15M | $42M | $93M | $60M | $64M | $58M | $49M | $47M |
| Shareholders' equity | $223M | $263M | $264M | $288M | $272M | $287M | $286M | $212M | $154M | $143M |
| Net debt | -$104M | -$133M | -$89M | -$157M | -$96M | -$94M | -$86M | -$69M | -$56M | -$57M |
Cash flow
Fiscal years, from Anika Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $24M | $41M | $35M | $37M | $13M | $8M | $4M | -$2M | $5M | $11M |
| Capital spending | $14M | $9M | $5M | $3M | $2M | $5M | $7M | $5M | $8M | $7M |
| Free cash flow | $10M | $32M | $30M | $34M | $11M | $3M | -$3M | -$7M | -$2M | $4M |
| Stock-based compensation | $3M | $6M | $11M | $6M | $5M | $11M | $14M | $15M | $13M | $10M |
| Share buybacks (net) | -$25M | — | -$30M | -$30M | $0 | $0 | $0 | -$5M | -$11M | -$9M |
| Net borrowing | — | — | $0 | $0 | -$350,000 | $0 | $0 | — | — | — |
| Free cash flow margin | 10.1% | 28.1% | 28.7% | 29.8% | 8.8% | 2.2% | -2.7% | -6.0% | -1.9% | 3.9% |
Questions
What was Anika Therapeutics's revenue in 2025?
$113M in fiscal 2025, from its 10-K filing.
How much free cash flow does Anika Therapeutics generate?
$4M in fiscal 2025 (operating cash flow minus capital spending).
From Anika Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.